Tech Company Financing Transactions
Amplyx Pharmaceuticals Funding Round
On 5/20/2020, Amplyx Pharmaceuticals raised $53 million in Series C investment from Sofinnova Ventures, 3x5 Partners and Adage Capital Management.
Transaction Overview
Company Name
Announced On
5/20/2020
Transaction Type
Venture Equity
Amount
$53,000,000
Round
Series C
Investors
Proceeds Purpose
The company will use the proceeds of the financing to advance the clinical development of its product candidates, fosmanogepix and MAU868.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12730 High Bluff Dr. 160
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Grey
Chief Executive Officer
Ciara Kennedy
Chief Financial Officer
Alan Fuhrman
Chief Medical Officer
Michael Hodges
VP - Bus. Development
Kevin Holme
VP - Operations
Paul Bien
VP - Operations
Pamela Wedel
VP - Regulatory Affairs
Elizabeth Gordon
Browse more venture capital transactions:
Prev: 5/20/2020: Nivagen Pharmaceuticals venture capital transaction
Next: 5/20/2020: Leafly venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs